Obermatt
See Similar Stocks →

Alector

NSQ:ALEC · US0144421072
BiotechnologySmall

360

15
Profit price13
Cash yield1
Price/Sales52
Price/Book76
Return on Capital13
Cash Return on Capital4
Return on Equity6
Profit margins26
Accruals88
Owner Earnings Margin38
Sales growth13
Profit growth58
Reinvestment100
Price momentum30
Debt load10
Refinancing10
Debt Payback1
Liquidity62
Analyst ratings5
Opinion Changes17
Price Target Upside34
Market mood22
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Alector doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2017
Employees139
Websitealector.com
ISINUS0144421072
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyGeneticsNeuroscienceCentral Nervous SystemBiotechnologyHealth CareTherapeutics

Description

Alector, Inc. (Alector) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. The company is advancing a portfolio of programs focused on genetically validate…

Analysis

Middle-of-the-road

Alector, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
8
2026

All-time high

39

Mar 2026

All-time low

8

Jun 2026

Average rank

24

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
52
—
—
—
Price/Earnings
21
—
—
—
Price/Book
76
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
75
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Alector with its peers
Denali Therapeutics
NSQ:DNLI
37
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Candel Therapeutics
NMQ:CADL
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Celldex Therapeutics
NAQ:CLDX
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Aura Biosciences
NMQ:AURA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immunitybio
NSQ:IBRX
19
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →